Past Meetings
- joanna.lewis
- Joseph Standing
- r.hoare.11
- Julie Bertrand (Deactivated)
Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.
Meeting date | Uploaded by | Slides | Comments |
|---|---|---|---|
2 May 2012 | Julie | PFIM Interface 3.1 - cours M2R 10-11.pdf | |
15 May 2012 | Angelina | ||
6 June 2012 | Joe | ||
13 June 2012 | Joanna | EMA geriatric workshop - March 2012 - Shepard (submitted 19March).ppt | Terry Shepard's Slides |
12 October 2012 | Rollo | ||
9 November 2012 | Joanna | ||
13 November 2012 | Julie | ||
14 December 2012 | Lilia | Modelling neutrophil dynamics in children following bone marrow transplant | |
22 Februrary 2013 | Allienor Berges | ||
1 March 2013 | Rollo | ||
28 May 2013 | Charlotte |
9 May 2012 | PUW1 | Joanna | Immunology |
16 May 2012 | WCJ | Angelina | Zidovudine PK/PG |
23 May 2012 | PUW2 | Jig | LMWH in pregnancy |
30 May 2012 | No meeting | ||
6 June 2012 | PUW1 | Joe | Antimicrobial PKPD |
13 June 2012 | PUW1 | Terry Shepard | Geriatric PKPD |
20 June 2012 | PUW2 | Rollo/Joanna | Immunology modelling |
27 June 2012 | No meeting | ||
4th July 2012 | No meeting | ||
11th July 2012 | PUW2 | Julie | PAGE review |
18th July 2012 | PUW2 | Katie | Gentamicin in burns |
12/10/12 1pm | WCA | Rollo | Modelling of the immune reconstitution post BMT |
19/10/12 1pm | PUW3 | Joe | Prague Biometrics 2012;68:902-11 |
26/10/12 1pm | PUW3 | Charlotte | NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans |
2/11/12 1pm | PUW3 | Eva | Neogent (developing Bayesian therapeutic drug monitoring) progress |
9/11/12 1pm | PUW3 | Joanna | Inference methods course review |
16/11/12 1pm | PUW2 | General discussion | |
23/11/12 1pm | PUW3 | Julie | Covariate selection methods in pharmacokinetic modelling |
30/11/12 1pm | PUW3 | Julie | NCA versus modelling in phase I studies for drugs with long half-life |
7/12/12 1pm | PUW3 | Goldacre talk | |
14/12/12 1pm | PUW3 | Lilia | Neutropenia post-BMT |
4/1/13 1pm | PUW3 | General discussion | |
11/1/13 1pm | Levinsky | Joe | Maraviroc PK |
18/1/13 1pm | PUW4 | Andrezj | PKPD bridging of response between adults and children |
25/1/13 1pm | PUW3 | Lilia | Neutropenia following paediatric BMT |
1/2/13 1pm | PUW1 | Mirjam Trame | Use of PKPD modeling to guide HIV understanding and treatment |
8/2/13 1pm | PUW3 | Sami | Bioequivalence studies and genetic variability |
15/2/13 1pm | PUW1 | Liana | ErbB inhibition for PKD |
22/2/13 1pm | PUW3 | Alienor Berges (GSK) | |
1/3/13 1pm | PUW4 | Rollo | CD4 reconstitution post BMT |
8/3/13 1pm | PUW3 | Eva | Neogent update |
15/3/13 1pm | PUW4 | Tafi | Dose individualisation in HIV/AIDS and TB patients on Efavirenz (EFV). |
22/3/13 1pm | PUW3 | Hui Ma | Genetic components to glucose-insulin response |
26/4/13 1pm | PUW3 | Sarit | FA and bioavailability |
10/5/13 1pm | PUW3 | Tafi | Common adverse drug reactions linked to HIV and/or TB medication: Lipodystrophy, Skin Hypersensitivity, CNS and Peripheral Neuropathy. |
28/5/13 1pm | PUW1 | Charlotte | Use of meta-analysis in evidence synthesis: an example based on dose selection for antibiotics (PAGE talk) |
31/5/13 1pm | PUW1 | Rollo | Modelling immune reconstitution in children post HSCT (PAGE talk) |
7/6/13 1pm | PUW3 | Julie | Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy (PAGE talk) |
21/6/13 1pm | PUW1 | Bruce Green | Therapeutic Drug Monitoring |
16/9/13 1pm | PUW3 | Joe | Diagnostics for bivariate regression models |
23/9/13 1pm | PUW3 | No meeting | Julie Seminar on Tues 24/9. |
30/9/13 1pm | PUW2 | Jan-Stefan Van der Walt | Nonlinear mixed effects model for saliva cortisol and cortisone in patients with Addisons disease and healthy volunteers. |
1/10/13 1pm EXTRA MEETING | PUW4 | Stefanie Hennig | Changes in between subject variability with covariate models in pharmacometrics |
7/10/13 1pm | PUW2 | ||
14/10/13 1pm | PUW3 | Tafi | TBA |
21/10/13 1pm | PUW2 | Julie | Modelling of tenofovir and emtricitabine PK in the ANRS 134-COPHAR 3 trial (work in progress) |
28/10/13 1pm | PUW3 | Joanna | CD4 recovery in the CHER study |
4/11/13 1pm | PUW2 | Eva | Upgrade talk practice |
11/11/13 1pm | PUW3 | Flora Musuamba | Use of modelling and simulation tools to improve decision-making in drug development and clinical practice |
18/11/13 1pm | PUW2 | Joe | Decision theory and antimicrobials |
25/11/13 1pm | PUW3 | Andreas | Pain PKPD |
2/12/13 1pm | TWC F | No meeting | |
9/12/13 1pm | PUW3 | Pieter de Cock | Paediatric antimicrobial PKPD in ICU |
16/12/13 1pm | PUW3 | Rollo | Modelling TCR repertoire (not with NLME!) |
20/1/14 | PUW3 | Jessica Soto | Modelling taste studies |
27/1/14 | PUW1 | Joanna | Practice for South Africa |
3/2/14 | PUW3 | Liana | PK of tyrosine kinase inhibitors in PKD animal model |
10/2/14 | PUW4 | Eva | Neogent predictions |
17/2/14 | PUW3 | Deji | Hepatitis and HIV co-infection modelling |
24/2/14 | PUW1 | ||
3/3/14 | PUW2 | Rollo | Upgrade practice |
10/3/14 | PUW1 | Joe | Clonidine PKPD for sedation in PICU |
17/3/14 | PUW3 | Andreas | Clinical protocol development for GAbapentine in Paediatric pain Project : Optimization of the trial design characteristics based on (E)D optimality using popED. |
24/3/14 | PUW3 | Julie | MRC Biostats talk on new methods for genetic covariates in PKPD modelling. |
31/3/14 | PUW1 | Flora | Clinical protocol development for GAbapentine in Paediatric Pain Project : Dose rationale and dosing schedule for characterisation efficacy in chronic pain |
7/4/14 | PUW3 | Morris | Development and dose rationale for fixed dose combinations for the treatment of tuberculosis |
14/4/14 | WCD | Andrezj | Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality |
26/4/14 | PUW4 | ||
12/5/14 | PUW2 | Carlos Hoyo | Nifedipine PKPD |
19/5/14 | WCC | Gavin Jarvis | A Modelling Approach to the Genetics of Embryonic Growth |
23/6/14 | PUW3 | All | PAGE meeting review |
30/6/14 | PUW2 | Flora | NLME cluster demonstration |
7/7/14 | PUW1 | Sophie Rhodes | The immune response to BCG vaccination over time and the population variation of immune response dynamics |
14/7/14 | PUW2 | Joanna and Jamie | An ODE model of peptide presentation by MHC-I / Geometric MCMC |
SUMMER |
1/9/14 | LGSR | Joe | Antimicrobial PKPD IDM_clinpharm_Standing_2014.pdf |
8/9/14 meeting starts 2pm | Levinski | Julie | DDMore language |
15/9/14 | LGSR | Paul | Pharmacogenetics of diclofenac |
22/9/14 | LGSR | Yucheng | Count data models and introduction to Pirana |
29/9/14 | LGSR | Andreas | Gabapentin PKPD in paediatric neuropathic pain |
6/10/14 | LGSR | Liana | Tyrosine kinase inhibitor effects in polycystic kindney disease |
13/10/14 | LGSR | Joanna | |
20/10/14 | LGSR | Rollo | Short-term neutrophil and lymphocyte HSCT models |
27/10/14 | LGSR | Eva | NeoGent PKUK practice |
3/11/14 | LGSR | Seb | Item Response Theory: Application to NLME |
10/11/14 | LGSR | Joe | A new mechanistic model for antiretroviral pharmacodynamics |
17/11/14 | LGSR | Alberto | Anaesthesia depth with 3 different EEG measures |
24/11/14 | LGSR | Suzanne Reeves | Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease |
1/12/14 | LGSR | Deji | Mixed Effect Modelling in Hep C-HIV coinfected children |
8/12/14 meeting starts at 2pm | LGSR | TBC | To be confirmed |
15/12/14 | LGSR | Morris | Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 12/1/15 | PUW3 | Lynette Phee | Modelling antimicrobial synergy |
| 19/1/15 | PUW3 | Michael Betancourt | Bayesian approaches in NLMEM |
| 26/1/15 | PUW4 | Deji | pre-Upgrade Talk |
| 2/2/15 | PUW3 | Joe | Study design peer review/journal club |
| 9/2/15 | PUW3 | Eva | Comparing methods for paediatric PK scaling |
| 16/2/15 | PUW3 | Ajay Sinha | Amikacin and Vancomycin PK in neonates |
| 23/2/15 | PUW4 | Julie | Joint modeling of Tenofovir plasmatic and intracellular concentrations - The COPHAR3 trial |
| 2/3/15 | PUW3 | Karin Seifert | Establishing PK/PD relationships of anti-leishmanial drugs |
| 9/3/15 | PUW3 | Joe | Antimicrobial PKPD, refresher and future directions |
| 16/3/15 | PUW3 | Sophie | Vaccine dyamics with NLME |
| 23/3/15 | PUW4 | Suzanne | Amisulpride PKPD |
| 30/3/15 | PUW3 | Morris | Determinants of variability in drug exposure and implications for dose selection in tuberculosis patients |
| 13/4/15 | PUW2 | Andreas | Gabapentin for neuropathic pain |
| 20/4/15 | PUW3 | Joe | NLME tutorial |
| 27/4/15 | PUW4 | Yucheng | Propofol in ICU |
| 11/5/15 | PUW3 | Iblal | Benzylpenicillin neonatal PK |
| 18/5/15 | PUW3 | Joe | PK of combination therapy in resistant Gm -ves |
| 1/6/15 | PUW3 | ||
| 8/6/15 | PUW3 | Liana | PKPD of in vivo PKD model |
| 15/6/15 | PUW3 | All | PAGE review |
| 22/6/15 | PUW3 | Eva | PD neonatal infection modelling |
| 29/6/15 | PUW4 | Suzanne | PKPD of amisulpride |
| 6/7/15 | PUW3 | Ludo | PKPD in veterinary medicine |
| 13/7/15 | PUW3 | Roger Gunn | PK-PD modelling of CNS PET Molecular Imaging Studies |
| 7/9/15 | PUW3 | Aiwei | Dexmeditomidine PKPD |
| 14/9/15 | PUW3 | Eva | Meropenem in late onset sepsis and meningitis in neonates |
| 21/9/15 | PUW3 | Ludo | Dexmeditomidine PKPD (in veterinary subjects) |
| 28/9/15 | PUW3 | Ben | Modelling HCMV |
| 5/10/15 | PUW1 | Suzanne | Amisulpride PK update |
| 12/10/15 | PUW1 | David Moore | PKPD in TB |
| 19/10/15 | PUW1 | Joe | Personalised medicine with PKPD |
| 26/10/15 | PUW1 | Imperial Group | Antimicrobial decision support |
| 2/11/15 | PUW1 | ||
| 9/11/15 | PUW2 | Rollo | PhD viva prep talk |
| 16/11/15 | PUW2 | Eva | IRT for neonatal sepsis |
| 23/11/15 | PUW2 | Frank | PKPD in malaria |
| 30/11/15 | PUW2 | Morris | PBPK Modelling in TB |
| 7/12/15 | PUW2 | Liana | PKD PKPD |
| 14/12/15 | PUW2 | Pratima Chowdary | Individualised dosing in haemophilia |
Date
Location* | Presenter | Topic | |
|---|---|---|---|
| 1/2/16 | PUW3 | Deji | HIV models in children |
| 4/4/16 | PUW2 | Morris | Model-based translational research in tuberculosis |
4/7/16 | PUW2 | Albert | SiRNA PD in neuroblastoma |
| 6/2/16 | PUW1 | Charlotte | Update on NAPPA |
6/6/16 | PUW2 | No meeting | PAGE |
| 7/3/16 | PUW3 | Frank | In vitro TB PD |
9/5/16 | PUW3 | Joy Dawes | Morphine and dexmeditomidine PK in children |
| 11/4/16 | PUW3 | Oliver Stirrup | Adult NLME in HIV under HAART |
11/7/16 | PUW2 | No Meeting | To be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results |
13/6/16 | PUW2 | Georgie | Flucloxacillin PK: Neonatal results from NAPPA |
| 14/3/16 | PUW3 | Julie | Bayesian inference in high-throughput pharmacogenetics |
| 15/2/16 | PUW3 | Yucheng | Count data modelling of BATA |
16/5/16 | PUW3 | Julie | Joint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial |
| 18/1/16 | PUW3 | Planning meeting | |
| 18/4/16 | PUW3 | Ben | Incorporating immunity into CMV models |
20/6/16 | PUW2 | Dan Wright | Model-based dose prediction: the curious case of allopurinol |
| 21/3/16 | PUW2 | Deji | Modelling poor immune response in HIV-infected children |
| 22/2/16 | PUW3 | Ben | CMV model update |
23/5/16 | PUW2 | Letizia | PBPK in TB |
| 25/1/16 | Levinski room | Joe | Scaling in PK and PD |
| 25/4/16 | PUW3 | Per Olsson | Life as a pharmacometrics consultant |
27/6/16 | PUW2 | Salvo | Neonatal antimicrobial PK |
| 29/2/16 | PUW2 | Fabrizia | PKPD in neurology |
Date
Location* | Presenter | Topic | |
|---|---|---|---|
| 12/9/16 | PUW4 | Joanna Lewis | CHER, chlamydia and reproducibility: a view from Imperial |
| 19/9/16 | PUW4 | All | R-script repository |
| 26/9/16 | PUW4 | Ben | CMV PKPD update |
| 3/10/16 | PUW1 | Lucy Hutcinson | Preclinical PD modelling in oncology |
| 10/10/16 | PUW1 | Matt Jay | Bayesian analysis of morphine safety in children |
| 17/10/16 | PUW1 | Huixin Yu | PK/PD modelling & simulation for anticancer drugs with complex absorption characteristics |
| 24/10/16 | PUW1 | Morris | Modelling combination therapy in tuberculosis |
| 31/10/16 | PUW1 | Dagan Lonsdale | Update on ABDose |
| 7/11/16 | Levinsky | Aiwei Li | Dexmeditomidine PKPD |
| 14/11/16 | Levinsky | Amy Cheung/James Yates | QSP in paediatrics/Of mice and more |
| 21/11/16 | Levinsky | Grace | Neonatal and paediatric antimicrobials |
| 28/11/16 | Levinsky | ||
| 5/12/16 | Levinsky | ||
| 12/12/16 | PUW1 | Chris W | PBPK modelling of dexamethasone + selumetinib in combination in adults and children |
| 19/12/16 | PUW1 | Charlotte | Update on NAPPA |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 19/12/16 (12:00) | PUW1 | Charlotte | Update on NAPPA |
| 16/1/17 | PUW4 | Frank | Practice MRC interview |
| 23/1/17 | PUW4 | Joe | FLACSAM PK results |
| 30/1/17 | PUW4 | All | Paediatric sample size discussion |
| 6/2/17 | PUW4 | Frank | Update on treosulfan/TB work |
| 13/2/17 | PUW4 | Mike and Sophida | MRes project outline |
| 20/2/17 | PUW2 | Ben | CMV PD |
| 27/2/17 | PUW2 | Charlotte | NAPPA update |
| 6/3/17 | PUW2 | Morris | Rationale for dose selection in tuberculosis: how to scale from mouse to human? |
| 13/3/17 | PUW2 | Benjamin Blaise | iSleep/iCare - real-time metabolic support for personalized intensive care |
| 20/3/17 | PUW2 | ||
| 27/3/17 | PUW2 | Aubrey Cunningham | Adjunctive therapy for severe malaria |
| 3/4/17 | PUW2 | Belen | PhD update |
| 10/4/17 | PUW2 | ||
| 24/4/17 | PUW1 | Annegret Dahlmann-noor | PKPD in ophthalmology |
| 8/5/17 | PUW1 | Paul Baverel | Tralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan |
| 15/5/17 | PUW1 | Morris | TB modelling PAGE practice |
| 22/5/17 | PUW1 | Ben | CMV modelling ESPID practice |
| 5/6/17 | PUW1 | No meeting | |
| 12/6/17 (12:00) | PUW3 | All | PAGE review |
| 19/6/17 | PUW1 | Ludo | HFIM progress |
| 26/6/17 | PUW1 | Maria Scarpa | End-user acceptability of orodispersible films (ODF) for delivery of medicine |
| 3/7/17 | PUW1 | ||
| 10/7/17 | PUW1 | ||
| 17/7/17 | PUW1 |
| 30/10/17 | Levinsky | ||
| 27/11/17 | Levinsky | Waty | Covariate analysis with supervised machine learning |
| 25/9/17 | PUW2 | Yomna | Treosulfan PK |
| 23/10/17 | Levinsky | ||
| 20/11/17 | Levinsky | Nicolas Fanget | Publishing in Nature journals |
| 18/12/17 | Levinsky | Ludo | HFIM modelling progress |
| 18/9/17 | Levinsky | Sophida | Posaconazole pharmacokinetics in children |
| 16/10/17 | Levinsky | Mandy W | Vitamin D PKPD plans |
| 13/11/17 | Levinsky | Shan Pan | Application of pharmacometrics in rheumatoid arthritis: case studies in clinical practice and drug development |
| 11/12/17 | Levinsky | Vicky | Rivaroxaban PKPD |
| 11/9/17 | Levinsky | no meeting | |
| 9/10/17 | Levinsky | ||
| 6/11/17 | Levinsky | Julie | PK of serum and intra cellular sustained-release Lithium |
| 4/12/17 | Levinsky | Julie | PK of total, unbound and intra cellular MPA |
| 2/10/17 | Levinsky | Ofran | Gender differences in infant mortality in UK PICUs |
| 8/1/18 | PUW 4 | planning meeting | |
| 15/1/18 | PUW 4 | Haifa | Posaconazole study protocol |
| 22/1/18 | PUW 4 | Frank | Vancomycin PKPD |
| 29/1/18 | PUW 4 | Dagan | Results from ABDose |
| 5/2/18 | PUW 4 | Shan | Salbutamol PKPD |
| 12/2/18 | PUW 4 | Dionna | CoMPLEX mini project |
| 19/2/18 | PUW 3 | ||
| 26/2/18 | PUW 3 | Bern | TB-PRACTECAL trial PK-PD study design |
| 5/3/18 | Levinski 12:00 start | Ayesha | Rituximab PKPD |
| 12/3/18 | PUW 3 | Ben | Statistical Challenges in T Cell Receptor Repertoire Immunophenotyping |
| 19/3/18 | PUW 3 | Joe | Posaconazole PK |
| 26/3/18 | PUW 1 | Waty | Machine learning approaches |
| 9/4/18 | PUW 3 | ||
| 16/4/18 | PUW 3 | planning meeting | |
| 23/4/18 | PUW 3 | no meeting ECCMID | |
| 30/4/18 | PUW 3 | Jig | Anticoagulant PKPD in haemodialysis |
| 14/5/18 | PUW 3 | Frank | Modelling progress in TB |
| 21/5/18 | PUW 3 | no meeting PK course | |
| 4/6/18 | PUW 3 | Maddlie | PhD introduction: PKPD modelling of sedative and analgesic effects |
| 11/6/18 | PUW 3 | Komal Bhatia | Infant growth in urban informal settlements (slums) in Mumbai, India |
| 18/6/18 | PUW 3 | Shan | Psoriasis PKPD modelling |
| 25/6/18 | PUW 3 | Oleg Volkov | Optimal design in PKPD |
| 2/7/18 | PUW 3 | Ben | CMV modelling |
| 9/7/18 | PUW 3 | Julie | Model-based bioequivalence |
| 3/9/18 | PUW 3 | planning meeting | |
| 10/9/18 | PUW3 | Frank | Modelling of in vitro antimicrobial experiments |
| 17/9/18 | PUW3 | no meeting | |
| 24/9/18 | PUW3 | Satveer | NIHR practice psoriasis TDM |
| 1/10/18 | PUW1 | Ofran | NIHR practice |
| 8/10/18 | PUW1 | Julie | Dynamic individual predictions of biomarker profiles and survival in Oncology with Stan, Monolix and Nonmem |
| 15/10/18 | PUW1 | ||
| 22/10/18 | PUW3 | Rashmi Kulkarni | Monitoring oxidative stress enables predictions of personalised glucose targets in diabetic patients |
| 29/10/18 | PUW3 | ||
| 5/11/18 | PUW3 | James Yates | Modelling nonclinical efficacy data for immune-oncology treatments |
| 12/11/18 | PUW3 | Frank | Vancomycin PKPD in children |
| 19/11/18 | PUW1 | John | PhD introduction - nlme in vaccine development |
| 26/11/18 | Levinski | Soumya | PhD introduction |
| 3/12/18 | PUW3 | Jaya | Neonatal vancomycin CSF PK |
| 10/12/18 | PUW3 | Daren Austin | Optimised dose for WHO weight bands |
| 7/1/19 | PUW3 | Planning meeting | |
| 14/1/19 | PUW3 | Joe | BSAC Antimicrobial chemotherapy meeting practice |
| 21/1/19 | PUW3 | ||
| 28/1/19 | PUW3 | Maddlie | Clonidine/fentanil PK update |
| 4/2/19 | PUW1 | journal club | |
| 11/2/19 | PUW1 | Frank | Predicting clinical outcome in TB |
| 18/2/19 | PUW1 | Charlotte | NAPPA overview |
| 25/2/19 | PUW3 | Phil Tresadern | popypkpd introduction |
| 4/3/19 | PUW3 | Silke | PhD work summary |
| 11/3/19 | PUW3 | Ferran | PK paper picking with ML |
| 18/3/19 | PUW3 | Maddlie | PKPD of sedation in neonates |
| 25/3/19 | PUW3 | Jude | PhD Introduction |
| 1/4/19 | PUW1 | Soumya | Rituximab PD in BMT |
| 8/4/19 | LEWINSKY | Zoe | PhD Introduction |
| 15/4/19 | PUW3 | no meeting | ECCMID |
| 13/5/19 | PUW3 | Claire Deakin | Modelling long-term outcomes and estimating treatment efficacy in a rare rheumatic disease |
| 20/5/19 | PUW3 | Haifa | Caspofungin PK in ECMO |
| 3/6/19 | PUW1 | ||
| 10/6/19 | LEVINSKY | no meeting | |
| 17/6/19 | PUW3 | All | PAGE review |
| 24/6/19 | PUW3 | Cintia | Paediatric Clinical Pharmacology in Buenas Aires |
| 1/7/19 | PUW3 | Wen Yao | PKPd in Malaysia |
| 8/7/19 | PUW3 | Joe | Treo PKPD |
| 15/7/19 | PUW3 | Maddlie | Upgrade practice |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 2/9/19 | LGSR | Ferran | QSP machine learning practice |
| 12/9/19 [NOTE Thurs) | PUW2 | Palang Chotsiri and Richard Hoglund | Malaria PKPD |
| 16/9/19 | LGSR | Planning meeting | |
| 23/9/19 | LGSR | Simon | Peptide PKPD |
| 30/9/19 | LGSR | ||
| 7/10/19 | LGSR | ||
| 14/10/19 | LGSR | Julie | Pharmacogenomics and nlme - some applications |
| 21/10/19 | LGSR | Frank | TB PKPD |
| 28/10/19 | LGSR | Soumya | B cell reconstitution post HSCT and rituximab |
| 4/11/19 | LGSR | Ferran | PK parameter extraction with NLP |
| 11/11/19 | LGSR | Zoe | Fosfomycin PK in neonates |
| 18/11/19 | PUW2 | Joe | MRC interview practice |
| 25/11/19 | PUW1 | Maddlie | Clonidine PKPD in PICU |
| 2/12/19 | PUW2 | ||
| 9/12/19 | PUW2 | Silke | Antimicrobial PKPD |
| 16/12/19 | PUW2 | Zahra | Antimicrobial in vitro PKPD |
Date | Location* | Presenter | Topic |
| 7/9/20 | microsoft teams | Planning meeting | |
| 14/9/20 | microsoft teams | Joe | SARS-CoV-2 dynamics |
| 21/9/20 | microsoft teams | Soumya | B cell update |
| 28/9/20 | microsoft teams | Zoe | Upgrade practice |
| 5/10/20 | microsoft teams | Maddlie | EAPs conference practice |
| 12/10/20 | microsoft teams | Emma | EHR Prescribing patterns |
| 19/10/20 | microsoft teams | Jude | PhD progress update |
| 26/10/20 | microsoft teams | Mandy | Colecalciferol in children with chronic kidney disease |
| 2/11/20 | microsoft teams | Maddlie | SANNI update |
| 9/11/20 | microsoft teams | Silke | PTA of antimicrobials |
| 16/11/20 | microsoft teams | Haifa | Caspofungin PK in ECMO |
| 23/11/20 | microsoft teams | Zahra | Hollow fibre update |
| 30/11/20 | microsoft teams | Zoe | Benzinidazole |
| 7/12/20 | microsoft teams | Matt | Risperidone study |
| 14/12/20 | microsoft teams | Frank | TB |
| 21/12/20 | microsoft teams | James | PK/PD of MDR TB therapy |
| microsoft teams |
Date | Location* | Presenter | Topic |
|---|---|---|---|
| 4/1/21 | microsoft teams | Planning meeting | |
| 11/1/21 | microsoft teams | James | PKPD of MDR TB |
| 18/1/21 | microsoft teams | Ferran | PKPDai update |
| 25/1/21 | microsoft teams | Soumya | Rituximab PKPD |
| 1/2/21 | microsoft teams | Julie | TModel-based bioequivalence |
| 8/2/21 | microsoft teams | Ferran | PKPDai update |
| 15/2/21 | microsoft teams | Silke | Amp/gent update |
| 22/2/21 | microsoft teams | Saher | Teicoplanin pharmacokinetics |
| 1/3/21 | microsoft teams | Frank | Journal club |
| 8/3/21 | microsoft teams | Najla | PhD introduction |
| 15/3/21 | microsoft teams | Nadhia | |
| 29/3/21 | microsoft teams | Emma | Pre-upgrade |
| 12/4/21 | microsoft teams | planning meeting | |
| 19/4/21 | microsoft teams | Vijay Ivaturi | Pumasai |
| 26/4/21 | microsoft teams | ||
| 10/5/21 | microsoft teams | Jude | Tacrolimus update |
| 17/5/21 | microsoft teams | Soumya | B cell update |
| 24/5/21 | microsoft teams | Ludo | |
| 7/6/21 | microsoft teams | ||
| 14/6/21 | microsoft teams | Jude | Tacrolimus update |
| 21/6/21 | microsoft teams | Frank/Bern | TB trial |
| 28/6/21 | microsoft teams | Emma | Upgrade practice |
| 5/7/21 | microsoft teams | Zoe | Benzinidazole |
| 12/7/21 |
| 13/9/21 | microsoft teams | Planning meeting | |
| 20/9/21 | microsoft teams | Akosua | Mechanism based antimicrobial PKPD |
| 27/9/21 | microsoft teams | Zonghui | Vitamin D PKPD |
| 4/10/21 | microsoft teams | Soumya | B cell dynamics under anticancer therapies |
| 11/10/21 | microsoft teams | Quentin | Exploring the risk of AMR horizontal gene transfer by transduction in S. aureus during phage-antibiotic co-therapy |
| 18/10/21 | microsoft teams | Emma | Antimicrobial time series update |
| 25/10/21 | microsoft teams | ||
| 1/11/21 | microsoft teams | Fan | Favipiravir PKPD |
| 8/11/21 | microsoft teams | Zoe | PKPD of immunosuppressant-azole interactions |
| 15/11/21 | microsoft teams | Vicky | PKPD of rivaroxaban |
| 22/11/21 | microsoft teams | Zahra | Antimicrobial in vitro PD |
| 29/11/21 | microsoft teams | Frank | TB Practical |
| 6/12/21 | microsoft teams | Jude | Tacrolimus PKPD |
| 13/12/21 | microsoft teams | Najla | Fosfomycin in vitro PKPD |
| 12/1/22 | PUW4/ microsoft teams | Marie Sjölin Wijk | |
| 24/1/22 | PUW4/microsoft teams | Stefano | |
| 31/1/22 | PUW4/microsoft teams | Andrew Mead | |
| 7/2/22 | PUW3/microsoft teams | Hui | Machine learning based model fitting |
| 14/2/22 | PUW3/microsoft teams | Carol | Bivalirudin PKPD |
| 21/2/22 | PUW3/microsoft teams | Zoe | Posaconazole PKPD |
| 28/2/22 | PUW3/microsoft teams | Najla | Fosfomycin hollow fibre |
| 7/3/22 | PUW3/microsoft teams | Vicky Smith | Automated parameter extraction |
| 14/3/22 | PUW3/microsoft teams | Akosua | FLARE trial PKPD |
| 21/3/22 | PUW3/microsoft teams | Fan | Favipiravir PKPD |
| 28/3/22 | PUW3/microsoft teams | Emma | Antimicrobials update |
| 4/4/22 | PUW3/microsoft teams | ||
| 25/4/22 | PUW3/microsoft teams | Jude | Tacrolimus PKPD |
| 9/5/22 | PUW3/microsoft teams | Helen Shaw | Pharmacokinetic Challenges for a Children’s Medicine Company |
| 16/5/22 | PUW3/microsoft teams | ||
| 23/5/22 | PUW3/microsoft teams | Amanda Gwee | Paediatric PKPD down under |
| 6/6/22 | PUW3/microsoft teams | Zhonghui | Progress with GA modelling |
| 13/6/22 | PUW3/microsoft teams | Fan | Favi update |
| 20/6/22 | PUW3/microsoft teams | Soumya | B cell dynamics in BMT |
| 27/6/22 | PUW3/microsoft teams | Jamie Dean | Introducing the Computational Radiation Biology and Oncology Lab |
| 4/7/22 | PUW3/microsoft teams | ||
| 11/7/22 | PUW3/microsoft teams | ||
| 18/7/22 | PUW3/microsoft teams | Emma | Predicting antimicrobial susceptibility to blood culture results |
| microsoft teams |
| 16/1/23 | PUW3/ microsoft teams | Soumya | PhD overview/viva practice |
| 23/1/23 | PUW3/microsoft teams | Shan | Adalimumab PKPD |
| 30/1/23 | PUW3/microsoft teams | Suzanne | Piperacillin-tazobactam PKPD |
| 6/2/23 | PUW3/microsoft teams | Vicky | PhD update |
| 13/2/23 | PUW3/microsoft teams | Ludo/Andrew | Modelling the effect of Antimicrobial use in poultry on AMR risk in 3 Asian countries / Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine |
| 20/2/23 | PUW3/microsoft teams | Hui | PhD update |
| 27/2/23 | PUW3/microsoft teams | Jude | Tacrolimus PKPD |
| 6/3/23 | PUW3/microsoft teams | ||
| 13/3/23 | PUW3/microsoft teams | Rachel | Project introduction |
| 20/3/23 | PUW3/microsoft teams | Najla | Systematic review |
| 27/3/23 | PUW3/microsoft teams | Emma | Antibiotic prescribing in remote versus face-to-face consultations for acute respiratory infections in English primary care: An observational study using TMLE |
| 17/4/23 | PUW3/microsoft teams | Vicky | Upgrade talk |
| 24/4/23 | PUW3/microsoft teams | Najla | Antimicrobial PKPD systematic review |
| 15/5/22 | PUW3/microsoft teams | Joe | Panoramic practice |
| 22/5/22 | PUW3/microsoft teams | Joe | FDA talk practice |
| 5/6/23 | PUW3/microsoft teams | Simone Perazzolo | Introduction to the SAAM2 software |
| 12/6/23 | PUW3/microsoft teams | Hui | PAGE meeting practice |
| 19/6/23 | PUW3/microsoft teams | Hui | PhD upgrade |
| 26/6/23 | PUW3/microsoft teams | PAGE | |
| 3/7/23 | PUW3/microsoft teams | WCP | |
| 10/7/23 | PUW3/microsoft teams | Rachel Clapham | PopPk of edoxaban |
| PUW3/microsoft teams |
| 5/9/22 | PUW3/ microsoft teams | Jeff Barrett | Model-informed Pediatric Drug Development |
| 12/9/22 | PUW3/microsoft teams | Akosua | SARS-CoV-2 viral dynamics |
| 19/9/22 | PUW3/microsoft teams | ||
| 26/9/22 | PUW3/microsoft teams | Fan | Upgrade practice |
| 3/10/22 | PUW3/microsoft teams | Najla | Upgrade practice |
| 10/10/22 | PUW3/microsoft teams | Emma | Antibiotic prescribing and remote consultations in primary care |
| 17/10/22 | PUW3/microsoft teams | Ofran | TLMEs |
| 24/10/22 | PUW3/microsoft teams | Frank | ACoP practice |
| 31/10/22 | PUW3/microsoft teams | Reya | PKUK practice |
| 7/11/22 | PUW3/microsoft teams | All | ACoP/PKUK review |
| 14/11/22 | PUW3/microsoft teams | Jig | Fellowship chalkboard |
| 21/11/22 | PUW3/microsoft teams | ||
| 5/12/22 | PUW3/microsoft teams | Dolapo Odujinrin | Introduction to PhD project |
| 12/12/22 | PUW3/microsoft teams | ||
| 4/9/23 | PUW3/ microsoft teams | planning meeting | |
| 11/9/23 | PUW3/microsoft teams | Frank | TB modelling update |
| 18/9/23 | PUW3/microsoft teams | Zhara | Antimicrobial PKPD |
| 25/9/23 | PUW3/microsoft teams | Lizzy | Proposal overview |
| 2/10/23 | PUW1/microsoft teams | Jig Patel | Fellowship practice |
| 9/10/23 | PUW1/microsoft teams | Jan Stefan | NONMEM tips and tricks |
| 16/10/23 | PUW1/microsoft teams | Rob | Antimicrobial TDM Pro/con debate |
| 23/10/23 | PUW1/microsoft teams | Dolapo | Investigating mechanistic modelling approaches for individualised dosing of cancer therapeutics. |
| 30/10/23 | PUW1/microsoft teams | Fan | Ciclosporin |
| 6/11/23 | PUW1/microsoft teams | Joy | Neonatal sedative maturation functions |
| 13/11/23 | PUW1/microsoft teams | Oliver | CART preclinical modelling |
| 20/11/23 | PUW1/microsoft teams | Hui | Automated model building update |
| 27/11/23 | PUW1/microsoft teams | Lizzy | Rituximab PKPD |
| 4/12/23 | PUW1/microsoft teams | Najla | Systematic antimicrobial PKPD review |
| 11/12/23 | PUW1/microsoft teams | Andrew Mead | Update on antimicrobial PKPD |
| 8/1/24 | PUW3/ microsoft teams | planning meeting | |
| 15/1/24 | PUW3/ microsoft teams | Hui | Infection seminar |
| 22/1/24 | PUW1/microsoft teams | Charlotte | PhD plan |
| 29/1/24 | PUW3/microsoft teams | Martin Johnson | Machine learning in PKPD |
| 5/2/24 | PUW3/microsoft teams | Jude | Tacrolimus PK |
| 12/2/24 | PUW3/microsoft teams | ||
| 19/2/24 | microsoft teams | Shengyuan | Antiviral PKPD |
| 26/2/24 | microsoft teams | Vicky | NLP update |
| 4/3/24 | PUW3/microsoft teams | Oliver | CART update |
| 11/3/24 | PUW1/microsoft teams | Fan | Ciclosporin PK |
| 18/3/24 | PUW1/microsoft teams | Jig | Anticoagulant PKPD |
| 25/3/24 | PUW1/microsoft teams | Orlagh | NIHR outline |
| 8/4/24 | PUW1/microsoft teams | Planning meeting | |
| 15/4/24 | PUW1/microsoft teams | No meeting | |
| 22/4/24 | PUW1/microsoft teams | Hiie | Exenatide PKPD |
| 29/4/24 | PUW1/microsoft teams | Abigail | Preclinical antimicrobial PKPD |
| 13/5/24 | PUW1/microsoft teams | Charlotte T | BSTOP PKPD |
| 20/5/24 | PUW1/microsoft teams | Yawen | Vincristine PKPD |
| 3/6/24 | PUW1/microsoft teams | Vicky | NLP/PKPDai |
| 10/6/24 | PUW1/microsoft teams | Hui | nlmixr2auto |
| 17/6/24 | PUW1/microsoft teams | Shengyuan | PANORAMIC PD model |
| 24/6/24 | PUW1/microsoft teams | ||
| 1/7/24 | PUW1/microsoft teams | Andrew | Combination antimicrobial PKPD |
| 8/7/24 | PUW1/microsoft teams | Fan | Immunoglobulin PD |
| 2/9/24 | PUW3/ microsoft teams | planning meeting | |
| 9/9/24 | PUW3/ microsoft teams | Rohan Benecke | Metformin Dosing in Obese HIV patients |
| 16/9/24 | PUW3/microsoft teams | Paolo Denti | Importance of BOV |
| 23/9/24 | PUW3/microsoft teams | Hui | Update following UPSS |
| 30/9/24 | PUW?/microsoft teams | Rob | Vancomycin real time PK |
| 7/10/24 | PUW2/microsoft teams | Jude | Tacrolimus update |
| 14/10/24 | PUW1/microsoft teams | Hiie | Novel antimicrobial modelling approach |
| 21/10/24 | PUW1/microsoft teams | Charlotte | 5-FC update |
| 28/10/24 | PUW1/microsoft teams | Arwa | Drug-radiotherapy combinations |
| 4/11/24 | PUW1/microsoft teams | Vicky | Table extraction and PKPDAI update |
| 11/11/24 | PUW?/microsoft teams | PKUK practice | Yawen, Arwa, Shengyuan |
| 18/11/24 | PUW2/microsoft teams | Shengyuan | SARS-CoV-2 viral dynamics |
| 25/11/24 | PUW1/microsoft teams | Jig | RISAPS trial analysis |
| 2/12/24 | PUW2/microsoft teams | Najla | Amikacin PK in neonates |
| 9/12/24 | PUW2/microsoft teams | Yawen | Antimicrobial PKPD |
| 16/12/24 | PUW3/microsoft teams | Dolapo | Dose Selection Strategies for CAR-T Therapy in Oncology |